GLPwatch
Smoking cessation
Investigational / off-label
Last updated 2026-05-28 15:46 UTCResearch suggests GLP-1 drugs may influence nicotine intake by acting on habenular avoidance circuits, while other studies in animal models explore potential pancreatic effects and broader applications of GLP-1 receptor agonists.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for smoking cessation in our data. Any research below reflects investigational or off-label study.
Research (23)
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- GLP-1 acts on habenular avoidance circuits to control nicotine intake.
- The benefits of GLP-1 drugs beyond obesity.
- The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.
- Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.
- Effects of dulaglutide on alcohol consumption during smoking cessation.
- Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.
- GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity.
- Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.
- Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.
- Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.
- Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial.
- Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation.
- A mouse model of weight gain after nicotine withdrawal.
- Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
- Smoke or fire? Acute pancreatitis and the liraglutide trials.
- Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!
- Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.
- Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial.
- Semaglutide: A New Medical Swiss Army Knife?
- A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.
- Therapeutic Potential of GLP-1 Receptor Agonists for Smoking Cessation.
Common questions
- Which GLP-1 drugs are FDA-approved for Smoking cessation?
- No GLP-1 drug is currently FDA-approved for smoking cessation; any use would be off-label or investigational.
- Is there research on GLP-1 drugs for Smoking cessation?
- GLPwatch tracks 23 research papers on GLP-1 drugs and smoking cessation. This research is investigational and does not imply FDA approval.